SCHEMBL4286458

SCHEMBL4286458

Cc1cn([C@H]2CC(OO)[C@@H](CO)O2)c(=O)[nH]c1=O

nearest known ligand 0.72

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
RNASE1 P07998 1/20 0.69
TK1 P04183 6/20 0.65
LMNA P02545 2/20 0.63
TSHR P16473 2/20 0.63
ALB P02768 1/20 0.63
PKM P14618 1/20 0.63
BLM P54132 1/20 0.63
PMP22 Q01453 1/20 0.63
CYP2D6 P10635 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22992460 1.00 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL27989242 1.00 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL19132672 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL2056647 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL16359947 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL523267 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL12670320 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL25756080 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL10431982 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB
SCHEMBL523268 0.91 RNASE1 (0.69) RNASE1TK1LMNATSHRALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005058247-A2 METHOD FOR PREPARING RADIOLABELED THYMIDINE HAVING LOW CHROMOPHORIC BYPRODUCTS MOLECULAR TECHNOLOGIES, INC. (US) 2005-06-30 WO claimed
US-20050131223-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts CTI PET SYSTEMS, INC. 2005-06-16 US claimed
US-20090221530-A1 Relaxase Modulators and Methods of Using Same NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-09-03 US disclosed
US-7419653-B2 Method for preparing radiolabeled thymidine having low chromophoric byproducts SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2008-09-02 US disclosed
WO-2007056543-A2 RELAXASE MODULATORS AND METHODS OF USING SAME THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2007-05-18 WO disclosed
US-20070077198-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts WALSH JOSEPH C 2007-04-05 US disclosed
US-7160537-B2 Method for preparing radiolabeled thymidine having low chromophoric byproducts SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2007-01-09 US disclosed
WO-2005058247-A2 METHOD FOR PREPARING RADIOLABELED THYMIDINE HAVING LOW CHROMOPHORIC BYPRODUCTS MOLECULAR TECHNOLOGIES, INC. (US) 2005-06-30 WO disclosed
US-20050131223-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts CTI PET SYSTEMS, INC. 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131223-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts TYMP, TYMS, FLT1 RNASE1 2155/4885TK1 5/4885LMNA 1130/4885
US-20070077198-A1 Method for preparing radiolabeled thymidine having low chromophoric byproducts TYMP, TYMS, FLT1 RNASE1 2155/4885TK1 5/4885LMNA 1130/4885
US-20090221530-A1 Relaxase Modulators and Methods of Using Same RXFP1, RXFP2, RXFP4 RNASE1 50/4885TK1 830/4885LMNA 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.